Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis

OBJECTIVES: To describe the efficacy and safety through 5 years of adalimumab treatment in patients with ankylosing spondylitis (AS), and to identify predictors of remission. METHODS: Patients with active AS were followed up to 5 years during a 24-week randomised, controlled period, followed by an o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sieper, Joachim, van der Heijde, Désirée, Dougados, Maxime, Brown, L Steve, Lavie, Frederic, Pangan, Aileen L
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Group 2011
Assuntos:
Clinical and Epidemiological Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3329233/
https://ncbi.nlm.nih.gov/pubmed/22128084
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2011-200358
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados